Role of p53 family members p73 and p63 in human hematological malignancies
- PMID: 22497596
- DOI: 10.3109/10428194.2012.684348
Role of p53 family members p73 and p63 in human hematological malignancies
Abstract
p53, mutated in over half of human cancers and about 13% of all hematological malignancies, maintains genomic integrity and triggers cellular senescence and apoptosis of damaged cells. In contrast to p53, the homologs p73 and p63 play critical roles in development of the central nervous system and skin/limbs, respectively. Moreover, dependent on the context they can exert tumor suppressor activities that cooperate with p53. Unlike p53, p73 and p63 are rarely mutated in cancers. Instead, up-regulation of the anti-apoptotic dominant-negative ΔNp73 and ΔNp63 isoforms is the most frequent abnormality in solid cancers. In hematological malignancies the most frequent p73 defect is promoter methylation and loss of expression, associated with unfavorable clinical outcomes. This suggests an essential tumor suppressor role of p73 in blood cells, also supported by genetic mouse models. Many therapeutic approaches aiming to restore p73 activity are currently being investigated. In contrast, the most frequent p63 abnormality is protein overexpression, associated with higher disease grade and poorer prognosis. Surprisingly, although available data are still scarce, the emerging picture is up-regulation of transactivation-competent TAp63 isoforms, suggesting a tumor-promoting role in this context.
Similar articles
-
One, two, three--p53, p63, p73 and chemosensitivity.Drug Resist Updat. 2006 Dec;9(6):288-306. doi: 10.1016/j.drup.2007.01.001. Epub 2007 Feb 6. Drug Resist Updat. 2006. PMID: 17287142 Review.
-
Alterations of p63 and p73 in human cancers.Subcell Biochem. 2014;85:17-40. doi: 10.1007/978-94-017-9211-0_2. Subcell Biochem. 2014. PMID: 25201187 Free PMC article. Review.
-
The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.Histol Histopathol. 2015 May;30(5):503-21. doi: 10.14670/HH-30.503. Epub 2014 Dec 16. Histol Histopathol. 2015. PMID: 25510918 Review.
-
p63 and p73 in human cancer: defining the network.Oncogene. 2007 Aug 9;26(36):5169-83. doi: 10.1038/sj.onc.1210337. Epub 2007 Mar 5. Oncogene. 2007. PMID: 17334395 Review.
-
Differential regulation of p63 and p73 expression.Oncogene. 2003 Aug 28;22(36):5686-93. doi: 10.1038/sj.onc.1206859. Oncogene. 2003. PMID: 12944917
Cited by
-
Glyoxalase 2: Towards a Broader View of the Second Player of the Glyoxalase System.Antioxidants (Basel). 2022 Oct 28;11(11):2131. doi: 10.3390/antiox11112131. Antioxidants (Basel). 2022. PMID: 36358501 Free PMC article. Review.
-
Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.Br J Haematol. 2013 Dec;163(5):590-602. doi: 10.1111/bjh.12580. Epub 2013 Sep 30. Br J Haematol. 2013. PMID: 24117128 Free PMC article.
-
Prognostic Significance of p53 and p63 in Diffuse Large B-Cell Lymphoma: A Single-Institution Experience.Curr Oncol. 2023 Jan 17;30(2):1314-1331. doi: 10.3390/curroncol30020102. Curr Oncol. 2023. PMID: 36826063 Free PMC article.
-
A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome.Cell Death Dis. 2018 Sep 27;9(10):1011. doi: 10.1038/s41419-018-1042-7. Cell Death Dis. 2018. PMID: 30262802 Free PMC article.
-
Investigation on the Potential Correlation Between TP53 and Esophageal Cancer.Front Cell Dev Biol. 2021 Oct 27;9:730337. doi: 10.3389/fcell.2021.730337. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34778250 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
